{
    "organizations": [],
    "uuid": "a7e7783bce48ebe986c295b36acc1fc7325f4f84",
    "author": "",
    "url": "https://www.reuters.com/article/brief-us-fda-accepts-bristol-myers-squib/brief-u-s-fda-accepts-bristol-myers-squibbs-application-for-opdivo-plus-yervoy-idUSASC09TQP",
    "ord_in_thread": 0,
    "title": "BRIEF-U.S. FDA Accepts Bristol-Myers Squibb's Application For Opdivo Plus Yervoy",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 23 AM / Updated 7 minutes ago BRIEF-U.S. FDA Accepts Bristol-Myers Squibb's Application For Opdivo Plus Yervoy Reuters Staff 1 Min Read March 27 (Reuters) - Bristol-Myers Squibb Co: * U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTS BRISTOL-MYERS SQUIBB’S APPLICATION FOR OPDIVO (NIVOLUMAB) PLUS YERVOY (IPILIMUMAB) FOR PREVIOUSLY TREATED PATIENTS WITH MSI-H OR DMMR METASTATIC COLORECTAL CANCER FOR PRIORITY REVIEW * U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTS BRISTOL-MYERS SQUIBB’S APPLICATION FOR OPDIVO (NIVOLUMAB) PLUS YERVOY (IPILIMUMAB) FOR PREVIOUSLY TREATED PATIENTS WITH MSI-H OR DMMR METASTATIC COLORECTAL CANCER FOR PRIORITY REVIEW * BRISTOL-MYERS SQUIBB CO - ‍FDA ALSO GRANTED OPDIVO PLUS YERVOY COMBINATION BREAKTHROUGH THERAPY DESIGNATION FOR THIS POTENTIAL INDICATION​ * BRISTOL-MYERS SQUIBB CO - FDA ACTION DATE FOR FURTHER REGULATION ON THE SBLA IS JULY 10, 2018 Source text for Eikon: Further company coverage:",
    "published": "2018-03-27T14:20:00.000+03:00",
    "crawled": "2018-03-27T14:33:08.036+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "updated",
        "minute",
        "ago",
        "fda",
        "accepts",
        "squibb",
        "application",
        "opdivo",
        "plus",
        "yervoy",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "squibb",
        "co",
        "food",
        "drug",
        "administration",
        "fda",
        "accepts",
        "squibb",
        "application",
        "opdivo",
        "nivolumab",
        "plus",
        "yervoy",
        "ipilimumab",
        "previously",
        "treated",
        "patient",
        "dmmr",
        "metastatic",
        "colorectal",
        "cancer",
        "priority",
        "review",
        "food",
        "drug",
        "administration",
        "fda",
        "accepts",
        "squibb",
        "application",
        "opdivo",
        "nivolumab",
        "plus",
        "yervoy",
        "ipilimumab",
        "previously",
        "treated",
        "patient",
        "dmmr",
        "metastatic",
        "colorectal",
        "cancer",
        "priority",
        "review",
        "squibb",
        "co",
        "also",
        "granted",
        "opdivo",
        "plus",
        "yervoy",
        "combination",
        "breakthrough",
        "therapy",
        "designation",
        "potential",
        "squibb",
        "co",
        "fda",
        "action",
        "date",
        "regulation",
        "sbla",
        "july",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}